MSN Home  |  My MSN  |  Hotmail
Sign in to Windows Live ID Web Search:   
go to MSNGroups 
Free Forum Hosting
 
Important Announcement Important Announcement
The MSN Groups service will close in February 2009. You can move your group to Multiply, MSN’s partner for online groups. Learn More
A Peaceful Place[email protected] 
  
What's New
  
  �?•�?·´`·.·�? �?/A>  
  Copyrights  
  Disclaimer  
  �?•�?·´`·.·�? �?/A>  
  Messages  
  General  
  Articles - Misc.  
  ADHD,ADD, Autism  
  �?Allergies �?/A>  
  Alternative & +  
  § Arthritis §  
  Depression  
  �?Diet �?/A>  
  �?Exercise �?/A>  
  Eyes  
  Fitness and Exercise  
  �? FM & CF �?/A>  
  Headaches  
  Herbs etc  
  IBS & Other DD's  
  �?•�?·´`·.·�?�?/A>  
  Liver  
  Lung Health  
  MS �?/A>  
  ◄Mycoplasms�?/A>  
  Osteoporosis  
  Pain-Coping  
  Skin Disorders  
  Sleep  
  �?Supplements  
  �?Toxins �?/A>  
  Humor �?/A>  
  Household ☼¿☼  
  Mind-Body-Spirit  
  Pictures  
    
  �?Links �?/A>  
  Snags  
  Sources & Resources  
  ≈☆≈E-Cards ≈☆�?/A>  
  Pesticides Exp  
  �?Organic Living  
  Organic Gardens  
  See the Most Recent Posts  
  
  
  Tools  
 
�? FM & CF �?/A> : International Conference: Viruses in CFS
Choose another message board
 
     
Reply
 Message 1 of 2 in Discussion 
From: Rene  (Original Message)Sent: 7/3/2008 7:35 PM

 

 


NEWS

Conference Report

The 6th International Conference on HHV-6 & 7 and satellite conference on Viruses in CFS held in Baltimore June 19- 23rd were very successful, with over 230 scientists and clinicians in attendance. We were also pleased to welcome representatives from five drug companies and half-dozen diagnostic companies who are exploring therapeutic options and new diagnostic assays.


Among the highlights:

International Conference on HHV-6 & 7:

Kazuhiro Kondo, MD, PhD, of the Jikei University Medical School in Tokyo identified a novel human herpesvirus-6 (HHV-6) protein present in Chronic Fatigue Syndrome (CFS) patients but not healthy controls that may contribute to psychological symptoms often associated with that and other disorders. (Read more...) [http://www.hhv-6foundation.org/PRKondo_PFS.pdf]


Italian researchers, professors Arnoldo Caruso of the University of Brescia and Dario Di Luca of the University of Ferrara presented data suggesting that human HHV-6 infects and persists in a dormant state in endothelial cells, the cells lining blood vessels, and that the latency protein U94 causes these cells to lose their ability to grow, to form new blood vessels, and to take part in healing processes. This finding has potential consequences for both cardiac disease and tumor control. (Read more�? [http://www.hhv-6foundation.org/U94DiLuca.pdf]


Danish scientists Professor Per Hollsberg, MD and his PhD student Vanda Lauridsen Turcanova from the University of Aarhus In Denmark demonstrated that HHV-6 activates endogenous retrovirus HERV-K18 with possible consequences for autoimmunity. Viral infections are known to worsen autoimmune conditions. (Read more�? [http://www.hhv-6foundation.org/PRK18retrovirus.pdf]


Dr. Jose Montoya, an infectious disease specialist at Stanford University, released preliminary findings on his double-blind placebo-controlled antiviral trial of Valcyte for a subset of patients displaying high antibody levels to human HHV-6 and Epstein-Barr virus (EBV).  Statistically significant cognitive improvement was noted in the Multidemensional Fatigue Inventory (MFI-20) Mental Fatigue subscale and on patient self-reported of cognitive functioning, but there was not a significant result on the overall MFI-20 index. Data from treadmill testing, cytokine analysis, gene expression and other viral markers is still pending and will be announced at a later date.


Symposium on Viruses in CFS & Post-viral Fatigue:

Brigitte Huber, PhD, of the Tufts University School of Medicine presented evidence at a medical conference that suggested a reactivated ancient retrovirus embedded in the human genome may be active in chronic fatigue syndrome (CFS) and multiple sclerosis (MS) patients. Dr. Huber found that both MS and CFS patients (whose illness had been triggered by infectious mononucleosis) were at a higher relative risk for containing a HERV-K18 variant known to be particularly potent at inducing superantigen activity. Superantigens are proteins that are able to induce a strong undifferentiated T-cell response believed to impair the regulation of the immune system over time.
(Read more...) [http://www.hhv-6foundation.org/prk18.pdf]


Birgitta Evengard, MD from the Karolinska Institute reported that 33 twin pairs discordant for CFS, the twins had higher median EBV Early Antigen antibody levels than matched controls. VCA and EBNA antibodies did not differ between the two groups. The median HHV-6 Antibody levels did not differ between patients and controls. The data on both is preliminary since only two dilutions were done. No data was supplied on whether there was a subset of patients with significantly elevated antibody levels to HHV-6.

 

OTHER NEWS IN HHV-6:

�?HHV-6A was associated with rhomboencephalitis in immunocompetent children, characterized by new onset seizures, ataxia and opsoclonus-myoclonus. (Crawford 2007)

�?HHV-6 was found in 79% of lymph nodes from Hodgkin’s Lymphoma patients
(Lacroix, 2007) compared to EBV in 62%.

�?HHV-6B was associated with post-transplant acute limbic encephalitis, characterized by anterograde amnesia, syndrome of inappropriate antidiuretic hormone secretion and temporal lobe abnormalities. (Seeley 2007)

�?HHV-6 antibody titers were elevated in army recruits six to 12 months previous to diagnosis with schizophrenia (Niebuhr, 2007)

�?HHV-6 was frequently found in the gastroduodenal mucosa of transplant and immunocompetent patients with gastroenteritis; 94% of transplant recipients with biliary complications had HHV-6 or CMV in the duodenal mucosa. (Halme 2008)

�?Two thirds of resections from patients with refractory mesial temporal lobe epilepsy (MTLE) were found to have very high levels HHV-6B infection (Fotheringham, 2007); chronic viral infection may alter glutamate transport to cause seizures. (Fotheringham b, 2007)

 
[http://www.hhv-6foundation.org/]

Note:  The links to the articles above do provide some very thought provoking research ~ which I'm always open to - especially since the first rheumatologist I saw was so happy to label personality characteristics which must surely be the cause of my condition ! - lol  ~ Rene M

 


 



First  Previous  2 of 2  Next  Last 
Reply
 Message 2 of 2 in Discussion 
From: ReneSent: 7/3/2008 7:50 PM

 

Infection Update—Biofilms, HHV-6, Valcyte and CFS

Summary

New research is coming out giving us a clearer understanding of what is needed to fight infections in general, and especially in chronic illnesses like Chronic Fatigue Syndrome and Fibromyalgia. In this article, we will talk about two new concepts that offer us more tools for, and insight into, eliminating these infections:

1.

Biofilms. Just as we have learned to fight infections by using antibiotics, bacteria are also adapting to survive. One way that they're doing this is by creating Biofilms. Biofilms represents a layer of bacteria and other organisms that live together in a jelly like film. This film protects them from antibiotics, ultraviolet light and other "predators" and makes them hard to kill. New research is suggesting ways to kill them—despite their protective layer.

2.

HHV-6 viral infections. As discussed in an earlier article on viral infections, HHV-6 is an important viral infection in CFS and other illnesses. New research presented this week at the HHV-6 conference in Baltimore Maryland showed that:

a)

HHV-6 makes a chemical that may contribute to the "brain
fog" seen in CFS.

b)

Using Valcyte to kill HHV-6 can improve the cognitive
dysfunction ("brain fog") seen in CFS.

c)

HHV-6 infection may also be responsible for many cases of bipolar illness and depression.

Biofilms

In standard medicine, we are used to looking for bacterial infections by taking a few bacteria and putting them into a growth medium to see how they will grow. We then add antibiotics to the growth medium to see which ones are effective against the bacteria and what dose is needed.

For early acute infections, this approach can be effective. What medicine has ignored, however, is that in chronic infections, both in humans and in nature in general, infections form their own "cities" called "biofilms." These biofilms are like a mucus (called "Extracellular Polymeric Substances" or EPS) secreted by the organisms, and leave the infections highly resistant to antibiotics. Often, a number of different bacteria or fungi live in the same biofilm.

Because standard culturing techniques will not pick up most biofilms, medicine tends to treat these as if they are sterile fluid collections. Common examples of these would include "nonbacterial" prostatitis, dental infections, sinusitis and infections of medical materials such as implants or catheters.

Although just starting to become available, new tests such as PCR or antigen testing offer new hope for being able to diagnose and treat these biofilm infections. This is critical, as it is estimated that 65-80% (according to Center for Disease Control estimates) of human infections are caused by biofilms—which our current testing routinely misses.

As our awareness of biofilms increases, new approaches are being developed to help fight them. For example, a simple mineral called "bismuth" has been shown to markedly disrupt biofilms in very low dose. Interestingly, this mineral is sometimes found in toothpaste. Dental plaque is one of the most common forms of biofilm infections, and has been decreasing considerably—possibly because of the bismuth (and also because of dental floss). Bismuth is now also being added to medical catheters to prevent infections. I suspect that fairly soon, as Medicine realizes that sinusitis also reflects a biofilm, bismuth will be tested in nasal spray form. In the interim, the Sinusitis Nose Spray I recommend (available from ITC Pharmacy by prescription: 303-663-4224) contains xylitol, which may have a similar effect.

For more information on biofilms: Biofilms and Chronic Infections. JAMA June 11, 2008. P 2682-3

HHV-6, Valcyte and Brain Fog

At last week's HHV-6 conference in Baltimore, Maryland, Dr. Montoya presented his research on the use of Valcyte to eliminate HHV-6 viral infections. As summarized by Kristin Loomis, president of the HHV6 Foundation: "Dr. Jose Montoya, an infectious disease specialist at Stanford University, released preliminary findings on his double-blind placebo-controlled antiviral trial of Valcyte for a subset of patients displaying high antibody levels to human HHV-6 and Epstein-Barr virus (EBV). Statistically significant cognitive improvement was noted in the Multidimensional Fatigue Inventory (MFI-20) Mental Fatigue subscale and on patient self-reported of cognitive functioning, but there was not a significant result on the overall MFI-20 index. Data from treadmill testing, cytokine analysis, gene expression and other viral markers is still pending and will be announced at a later date."

Basically, the early data suggest that the antiviral Valcyte is most effective against the symptoms of brain fog. Clinical experience suggests that in a significant number of people with CFS, the Valcyte can be very effective overall as well. As the Valcyte will not eliminate the infection completely, it is critical to treat with the entire "SHINE Protocol." This way your immune system can recover enough to eliminate the infection. We have found that by using the Valcyte along with the "SHINE protocol," we often get excellent results. I look forward to the release of Professor Montoya's complete study.

Interestingly, another study presented at the conference suggests that chronic HHV-6 infections can create a special protein that is commonly found in the brains of those with CFS but not in those that are healthy, and that this protein may contribute to the brain fog often seen in Chronic Fatigue Syndrome. "Causes of many chronic diseases are unknown and chronic viral infection is one of the most suspected candidates," said Dr. Kondo, who spent 20 years trying to identify the latent protein responsible for chronic CNS disease and mood disorders.

Research suggests that other "psychological problems" may also be caused by HHV-6 infection. 71% of CFS patients with psychological symptoms, 53% of depression and 76% of bipolar patients possessed the antibody against the SITH-1 protein—but healthy patients showed no evidence of this protein. Although there are many causes of depression, it is quite possible that Medicine has been trying to treat a brain infection with Prozac!

SEE:   [http://www.endfatigue-dev.com/health_articles_f-n_2/Infections-update_biofilms_hhv-6_valcyte_cfs.html]

and   [http://www.endfatigue.com/health_articles_f-n/Infections-treating_hidden_viral_infections_cfs.html]